Market Access FDA approval numbers soar after COVID troubles The FDA released its overview of 2023 and the drugs it had approved during the year.
Events Partner Content 3rd Annual Complement-based Drug Development Summit 2019 November 13-15, 2019 | Boston, MA
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.